TWENTY-FIVE YEARS AGO: THEN AND NOW

Of interception, postcoital contraception and the morning after

Lindsay Edouard, FRCOG, MFFP, International Advisor, Journal of Family Planning and Reproductive Health Care

Reflecting interest in emergency contraception in the mid-1970s, ‘The Morning After’ was the title of the daily newspaper of the Sixtieth Annual Conference of the Planned Parenthood Federation of America held in New York. Attending the conference during transatlantic study leave, the Honorary Secretary of the National Association of Family Planning Doctors was impressed during the reception at the ‘Windows on the World’ restaurant atop the World Trade Center when ministers of religion described their advocacy role in the family planning movement.

Meanwhile, in the UK, official recommendations for improving access to oral contraception did not specifically mention its postcoital use to reduce recourse to abortion. Noticing numerous requests for abortion after a contraceptive consultation and whilst awaiting menstruation for the insertion of a copper-containing intrauterine device, a medical practitioner suggested that ‘if it is inserted within a week after ovulation, a device may prevent conception’.

Postcoital effects of stilboestrol, a non-steroidal oestrogen, were found soon after its discovery in the 1930s but societal attitudes were not conducive to further developments for another three decades, synthetic sex steroids being available by then. High doses of either stilboestrol or synthetic steroidal oestrogens, such as ethynylestradiol, were being used for emergency contraception in the early 1970s when the value of d-norgestrel was recognised. Norgestrel, a so-called ‘second-generation’ progestogen, was already an ingredient in various formulations of combined oral contraceptives that started to be used for emergency contraception, albeit in self-directed haphazard schedules. In 1977, Albert Yuzpe demonstrated the combined value of ethynylestradiol and norgestrel in the regimen that became standard. Norgestrel is a racemate with two equal parts: a biologically inactive enantiomer and an active one, hitherto called d-norgestrel according to its chemical configuration, but known since 1977 as levonorgestrel with the adoption of light rotatory nomenclature.

Several obstacles had to be overcome to improve access. Use of the precise term interception led to the mode of action of postcoital contraception being misconstrued as being abortifacient whereas confusion regarding its effectiveness, particularly beyond the morning after, caused ‘trick or treat’ doubts. In the absence of a dedicated product, the numerous pills in a dose caused inconvenience. Moreover, there was little incentive in seeking, from drug regulatory authorities, the approval of another indication regarding a product that was already on the market. Finally, practitioners were reluctant to exercise clinical judgement in prescribing oral contraceptives for an unlicensed indication.

Emergency contraception remained a closely guarded jewel in the black bag of select practitioners for another two decades. Its demystification, through advocacy and service delivery guidelines, was soon followed by the unequivocal demonstration of the comparative advantage of the levonorgestrel-only method. The World Health Organization (WHO) has stated that ‘emergency contraceptive pills do not interrupt pregnancy and thus are no form of abortion’ besides pointing out their value for adolescents as they tend to be sexually active before seeking contraceptive services. Access to emergency contraception has improved lately through deregulation with over-the-counter sales, school-based clinics and advice telephone lines with toll-free numbers such as NOT-2-LATE.

Editor’s Note. In the UK the pharmacy provision of Levonelle emergency contraception has recently been challenged and taken to judicial review. Anne Weyman, Chief Executive of fpa (formerly the Family Planning Association) which is one of the interested parties in the judicial review, attended the judicial review and in this commentary explains the process and the possible consequences should the review find against pharmacy provision of Levonelle. The outcome of the judicial review will be formally reported in the July issue of The Journal of Family Planning and Reproductive Health Care.

Commentary: Judicial review of the pharmacy provision of emergency contraception in the UK

Anne Weyman, OBE, Chief Executive, fpa, 2–12 Pentonville Road, London N1 9FP, UK

It seems extraordinary that more than 30 years after hormonal emergency contraception started to be used in the UK, the Society for the Protection of Unborn Children (SPUC) has been allowed a judicial review of the pharmacy provision of Levonelle. In mid-February, the High Court spent 3 days examining the impact of the 1861 Offences Against the Person Act on the provision of Levonelle and contraception more generally.
The Act includes two clauses which make it illegal for 'noxious substances' to be taken by or administered to a woman with the intention of causing a miscarriage. SPUC claimed that in 1861 pregnancy was understood to start with fertilisation and therefore, as one mode of action of Levonelle is to prevent implantation, it falls foul of this Act and, in fact, causes an abortion.

The Court considered a number of issues including the intention of Parliament when the 1861 Act was passed, the medical and everyday understandings of the term 'miscarriage' in 1861 and today, and to what extent, if any, the judge should take account of changes in technology, knowledge and social attitudes since 1861. SPUC's contention was that the intention of Parliament in 1861 was first, to protect the unborn child, and second, to protect women. There is a lack of contemporary evidence to support this view. Hansard does not contain any reference to discussion about these clauses when the 1861 Act was passed by Parliament. It is just as reasonable to believe that Parliament intended first to protect women, and second to protect the fetus.

In their submissions the Department of Health and Schering Health Care focused on developments in scientific knowledge, particularly embryology, the implications for this case of the 1990 Human Fertilisation and Embryology Act, and the outcomes of previous legal cases. In particular, there have been two criminal cases in which a doctor who was prosecuted for inserting an intrauterine device (IUD) for emergency contraception was found not guilty.

fpa was also a party to the case. Our evidence focused on the implications for women of a judgement in favour of SPUC. We pointed out that their argument would apply to the provision of hormonal contraception in any setting not just pharmacy. In addition, all other methods of contraception other than barrier methods, sterilisation and natural family planning may prevent implantation and, therefore, would be affected too.

The judge asked SPUC's barrister, Richard Gordon QC, whether he was able to demonstrate that a finding in SPUC's favour would only relate to Levonelle. Mr Gordon tried to do so, but his main point was that the case was not about other methods but if they were equally affected, so be it.

The judge indicated that he would hope to give his judgement either just before or just after Easter. As it would have such enormous consequences were he to find for SPUC, the Department of Health asked that the judgement should only be announced when Parliament is sitting and the judge agreed to this.

Statements on funding and competing interests
Funding. None declared.
Competing interests. None declared.
Commentary: Judicial review of the pharmacy provision of emergency contraception in the UK
Anne Weyman

*J Fam Plann Reprod Health Care* 2002 28: 105-106
doi: 10.1783/147118902101196117

Updated information and services can be found at:
http://jfprhc.bmj.com/content/28/2/105.2.citation

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/